Event Overview

Achieving excellence with R&D data will enable the life sciences industry to increase the speed and quality of innovation and is thus a major source of competitive advantage. Whether researchers and informaticians deal with “big data,” “deep data” or just put their data to smarter use, it is clear that the future of R&D is dependent on both smart technologies and clever researchers. The rapid progress of innovation in software and powerful hardware now allows human researchers to interpret masses of raw data in unique ways and is redefining the R&D business model. The benefits range from discovery and “omics” research, through to clinical trials and to real patients in the real-world. However, it is major technical, financial, and operational challenge is to turn “messy” data into structured data, that can be used for advanced analytics that can spot opportunities and achieve true insights. Some of the most promising areas of technological innovation making rapid progress include, for example, artificial intelligence, machine learning, cloud computing and the blockchain (distributed ledgers). There is also huge potential for efficient collaborations between the life science industry, technology companies, academic researchers, health systems, physicians, and health insurers to remove data silos. A deeper convergence between key stakeholders and advanced technologies will facilitate the discovery and development of powerful therapies, devices and advanced diagnostics to benefit patients.

The “R&D Data Intel Leaders Forum” is the must attend event for those senior decision-makers, researchers, data scientists and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D specific decision-making and intelligence.

Speakers List

Pharma Industry

Chief Scientific Officer
ERYTECH Pharma, France

James Matcham

VP Early Biometrics and Statistical Innovation, Biopharma R&D
AstraZeneca

Head of Computational Life Science IT
Bayer

Director,Strategy- World Wide Research and Development
Pfizer, USA

Senior Director Computational Biology, Discovery Sciences
Janssen Research & Development

Senior Director, Real World Evidence – External Partnerships Global Commercial Strategy Organisation
Janssen

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

Health Informatics Director,
AstraZeneca, UK

Head of R&D G3O
Janssen, Belgium

Eike Staub

Director, Head of Oncology Bioinformatics
Merck

Stefan Jaroch

Head External Innovation Technologies, Global External Innovation & Alliances
Bayer

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

Senior Strategic R&D Operations Analyst
Merck

David Ruau

Head of Data Science Advanced Analytics Dept.
Bayer

AI Innovation Lead
UCB

Senior Investigator II, Modeling & Simulation, Data Science
Novartis

Biotechs

President & CEO
QR Pharma

CSO
Tecrea, UK

CSO/COO
Oncodesign, France

MedTech & Diagnostics

Senior Vice President Information Technology
Hartmann Group, Germany

Global Head of Technology & Innovation Management
Siemens Healthcare

Rita Mateus Seidl

Director External Innovation, Oncology Discovery
Roche Diagnostics, Switzerland

External Stakeholders

Ramon Maspons Bosch

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

Thematic Coordinator Molecular Diagnostics Center for Health & Bioresources
Austrian Institute of Technology, Austria

Professor of Pharmaceutical Technologies
University of Greenwich, UK

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

Bruno Silva

Head of Design and Product Development
Arnhold Institute for Global Health, USA

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

Gerald Striedner (TBC)

Ass. Professor
University of Natural Resources and Life Sciences

Technology Companies

CEO and Co-Founder
Phenomic AI

Head of Strategy
Horizon Discovery, UK

Data Analytics Specialist
Google Cloud, Switzerland

Event Structure

Photo Gallery

Event Program

Strategic Developments in R&D Innovation

Day 1 - 27th January, 2020

Stream Overview

Data is redefining the R&D model and enabling better decision-making and innovation. Senior-level thought leaders from both the R&D and technology perspectives will be presenting the best technologies and approaches of today which are already creating a proven impact in R&D and which will be crucial for the research demands of tomorrow. These speakers will also discuss which technological, financial, regulatory, and operational challenges need to be overcome to ensure that key insights are achieved, and that patients’ benefits are dramatically enhanced through R&D intelligence.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

What are the next steps in the evolution of R&D?

09.10
How digitalisation in healthcare could help save lives
  • Where does healthcare stand in terms of digitalisation 
  • What are the main challenges in digital healthcare?
  • How digitalisation could help overcome these challenges
  • What are the main technology trends in healthcare?

Senior Vice President Information Technology
Hartmann Group, Germany

09.40
Building the future of innovation in Pharma and Biotechs

What are the future strategic developments in Pharma and BioTech companies? How to bring medical research to the next level? Although healthcare companies have started to heavily invest on R&D innovation programs to ensure that they “reach the future”, the impact on those strategies on their day-to-day business has been relatively poor so far. Healthcare needs to offer “more value” for “less money” and “in less time”. The talk will explore a few ideas on how to help healthcare companies to streamline their R&D efforts (including the introduction of artificial intelligence) and bring innovation to the market faster.

Data Analytics Specialist
Google Cloud, Switzerland

10.10
Statistical innovation in early clinical development
James Matcham

VP Early Biometrics and Statistical Innovation, Biopharma R&D
AstraZeneca

10.40
Networking & Coffee Break
11.10
Strategic innovation management and partnership for driving R&D
  • Integrated diagnostic and therapeutic decision making along clinical pathways
    • Technology convergence
    • AI
    • Diagnostic imaging & molecular technologies
    • Integrated pathways
    • Patient journey

Global Head of Technology & Innovation Management
Siemens Healthcare

11.40
Strategic approach of integrating AI into drug discovery

Director,Strategy- World Wide Research and Development
Pfizer, USA

12.10
Operationalising your R&D digital strategy: From multiple failures to impact and success

Head of Computational Life Science IT
Bayer

12.40
Luncheon Break

INNOVATIVE APPROACHES TO R&D STRATEGY

13.40
New therapeutic options in Oncology: Innovation by using human red blood cells to treat cancer
  • Clinical efficacy for Asparaginase-loaded red blood cells in cancer tumor starvation
  • Utilizing natural red blood cell trafficking to build a highly differentiated immuno-therapy platform
  • Erythrocyte-encapsulated proteins for enzyme-based therapies
  • Pro & cons of having a real unique R&D platform

Chief Scientific Officer
ERYTECH Pharma, France

14.10
Proof of target and pathway engagement to de-risk clinical compounds
  • Most compounds go through the clinic by relying on target engagement
  • In neurodegenerative disorders, like Alzheimer's and Parkinson's disease, target engagement has failed to show efficacy in phase 3 clinical studies
  • To understand what the compound does in the brain, showing target engagement isn't enough, because a compound can bind to the desired site, but not affect a change. It is, therefore, imperative to show pathway engagement. e.g. How target engagement results in the reversal of the toxic cascade that leads to nerve cell death and improvement of cognitive, neuropsychiatric as well as physical symptoms.
  • Our lead compound, ANVS-401, shows that normalisation of axonal transport leads to increased levels of neurotransmitters and neurotrophic factors, lowering of inflammation and protection of nerve cells.
  • We have been able to follow and reverse every step of the toxic cascade in animals and we have shown the reversal of two steps in humans. In our two phase 2 studies in AD and PD patients, we want to look at every step of the cascade, prove not just target but also pathway engagement and de-risk our lead compound for the phase 3 studies.

President & CEO
QR Pharma

14.40
Blockchain to support precision medicine

Presentation on the feasibility and benefits of creating a vendor/pharma independent, open source, Blockchain network to keep the real identity of the patients protected while allowing the possibility to:

  • Link different anonymised datasets for more powerful advanced analytics
  • Link real world data with clinical trial data and diagnostics data
  • Seek additional patient consent
  • Inform patients on the outcome of the research they participated in and inform them on how their data is supporting novel medical research
  • Seek additional information from patients on treatment outcome
  • Empower the patients to choose which of their data can be used for what medical research

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

15.10
Networking & Coffee Break
15.40
Spinning up the AI flywheel: How to identify and roll-out opportunities for AI solutions
  • Shifting mindsets: Can AI solve this problem for me?
  • Getting started: From idea to prototype
  • Industrializing Successful prototypes

AI Innovation Lead
UCB

16.10
Prioritising your R&D & What constitutes an innovation worth paying for?
Reimbursement Perspective
Ramon Maspons Bosch

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

16.40
Panel Discussion: Technology and the future of medicine
  • R&D Innovation – External vs. Internal and where are the future blockbuster drugs coming from?
  • What are the key attributes of the future, visionary R&D leaders?
  • Data-driven drug development: Establishing strategy & data governance for an effective use of big data in the R&D process.
  • Harnessing the power of precision medicine and genomics through converging technologies.
  • AI and its impact on future of life sciences.

Chief Scientific Officer
ERYTECH Pharma, France

Head of Computational Life Science IT
Bayer

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

President & CEO
QR Pharma

Senior Vice President Information Technology
Hartmann Group, Germany

Ramon Maspons Bosch

Chief Innovation Officer
Catalan Agency for Health Quality and Assessment – AquAS

17.30
Closing remarks
17.40
End of day 1

18.30 NETWORKNG DINNER

External Innovation for Enhancing R&D

Day 2 - Stream 1 - 28th January, 2020

Stream Overview

This stream is focused on how pharmaceutical innovation can be enhanced through intelligent and novel external collaborations. Almost all pharma and medtech companies now believe that they key to innovation is not purely through performing R&D in-house, but through partnerships with biotechs, academic or government institutes to tap unique sources of knowledge, capabilities, resources and technologies. However, there are a myriad of different models of external collaborations, which may include classical one-on-one partnerships, but increasingly unique “open-innovation” or partnering with larger-scale R&D consortia to pool risks and resources and know-how. Attendees will hear real life case studies and success stories and learn about what collaborative models, practices and approaches have actually resulted in R&D innovations which promise great commercial success.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

STRATEGIC APPROACHES & DRIVERS OF EXTERNAL INNOVATION

09.10
Strengths and weaknesses of public private partnerships

Head of R&D G3O
Janssen, Belgium

09.50
Interdisciplinarity as cornerstone of healthcare's future

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

HIGH PERFORMING EXAMPLES OF EXTERNAL INNOVATION

10.30
A collaborative approach to neurology drug discovery
  • Creating outcome-focused collaborations with academia
  • Adapting to the needs of collaborative partners
  • The Therapeutic Innovation Group: A novel collaborative model

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

11.10
Networking & Coffee Break
11.40
An approach to external innovation: Bayer case studies
Stefan Jaroch

Head External Innovation Technologies, Global External Innovation & Alliances
Bayer

12.20
Critical successes and failures in partnering with healthcare

Senior Director, Real World Evidence – External Partnerships Global Commercial Strategy Organisation
Janssen

13.00
Luncheon Break
14.00
Moving from in-house discovery to differentiation through identification
Rita Mateus Seidl

Director External Innovation, Oncology Discovery
Roche Diagnostics, Switzerland

BIOTECH PERSPECTIVES

14.40
External innovation technology company: A case study
  • Building the company: The bootstrapping model or “hybrid business model”
  • The integrated technology platform: A precision medicine drug discovery engine
  • Innovative asset creation: An example
  • Making the switch: From a technology CRO to a biopharmaceutical powerhouse

CSO/COO
Oncodesign, France

15.20
Networking & Coffee Break
15.50
Collaborating with external partners
  • Nanocin platform: Improving cell and tissue delivery of reagents and drugs.
  • Building the company: advancing one technology in three sectors
  • Working with partners
  • Partner projects examples in drug development
  • In-house asset development approach

CSO
Tecrea, UK

16.30
Panel discussion: New external innovation models for life sciences
  • Open-source and crowd-sourced R&D models: Examples
  • Private-public product development partnerships: Concrete examples for both EU and the US
  • Best practices in working with larger-scale R&D consortia: Organisation, coordination, practices, systems, technologies and people.
  • Partnering with technology companies: How emerging high-tech companies can forge win-win alliances with the life science industry via open innovation.

Head of R&D G3O
Janssen, Belgium

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

CSO
Tecrea, UK

Rita Mateus Seidl

Director External Innovation, Oncology Discovery
Roche Diagnostics, Switzerland

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

17.10
Closing remarks
17.20
End of day 2

Discovery & Omics Data Excellence

Day 2 - Stream 2 - 28th January, 2020

Stream Overview

This stream will focus on how to plan and implement data-driven approaches in the drug discovery process to unlock innovation. Huge volumes of raw data can be merged with other data sets, structured, and analysed from a myriad of perspectives, not just to achieve answers to complex research questions, but also to develop new hypotheses. Attendees will understand how a dedicated R&D data strategy for precision medicines and large “Omics” data volumes can achieve deep insights that enhance R&D decision making and innovation.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

PRECISION MEDICINE IN ACTION

09.10
Respiratory disease and robust stratification for precision medicine

Abstract: One of the promises of Biomedical Big Data is that it will resolve apparently homogenous patient cohorts into subtypes united by common pathophysiology. These subtypes can then be more effectively targeted with individualised therapies for more effective and efficient treatment. However, despite great promise and need, we remain at the beginning of this process, mired in the initial problem of how to identify a patient subpopulation. Here I reflect on the difficulties of subtyping, how it can go astray and how we were able to robustly define molecularly distinct subtypes in a richly detailed asthma cohort.

Health Informatics Director,
AstraZeneca, UK

09.50
RNA medicine meets systems biology: Precision medicine tools to optimise next generation drug development

We are in the dawn of a new era of RNA therapeutics in which precisely targeted RNA molecules exert powerful effects to selectively eliminate cancer cells, restore homeostasis or address disease processes with minimal side-effects. In addition, systems biology approaches to understanding function are supporting powerful new drug target discovery programmes. We explore both the possibilities and the reality of bringing together these novel paradigms to forge new high precision medicines.

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

10.30
Metabolic phenotyping in medicine and personalised medicine

Professor of Pharmaceutical Technologies
University of Greenwich, UK

11.10
Networking & Coffee Break

INNOVATIVE APPROACHES TO DRUG DISCOVERY

11.40
Single cell technologies for drug discovery, target identification and new mechanisms
12.20
Epigenomics and immunomics pipelines assisting minimal invasive diagnostics & biomarker development

Thematic Coordinator Molecular Diagnostics Center for Health & Bioresources
Austrian Institute of Technology, Austria

13.00
Luncheon Break
14.00
Industrialising early stage target discovery with deep-learning and high-content imaging
  • Early stage screens are shifting towards complex physiologically relevant models, with image-based readouts, yet this creates and image analysis nightmare
  • By using deep convolutional neural networks to analyse raw imaging data we can now effectively relive this bottle neck and run screens of thousands of conditions against complex multi-cellular and 3D models
  • In turn this has allowed us to identify novel targets involved in fibroblast activation that we are now developing and validating therapeutic antibodies against

CEO and Co-Founder
Phenomic AI

14.40
CRISPR-based functional genomics: From data to drugs
  • Assessing the impact of CRISPR-based approaches to the drug discovery process
  • Evolution of analytical and informatics approaches: where less is more, and more is better
  • Understanding new data features and a new standard of data quality
  • Global harmonisation and application processes for a cleaner data repository

Head of Strategy
Horizon Discovery, UK

15.20
Networking & Coffee Break
15.50
ATLAS - A precision health equity
  • Translating human systems into innovation opportunities for technology
  • Leveraging partners and stakeholders for innovation co-creation
  • Design-led technological innovations for ingesting complex data sources.
  • Challenges in implementing generalizable technological innovations for ingesting heterogeneous data.
Bruno Silva

Head of Design and Product Development
Arnhold Institute for Global Health, USA

16.30
Panel Discussion: Impact of high-performance computing on drug discovery and translational science
  • Utilising Big Data, focusing specifically on two phases of research: discovery, translational.
  • Next-Generation Sequencing, proteomic & genomic Big Data as a source of developing new biomarkers & personalised medicines. How do we deal with the data bottleneck?
  • Precision medicine tools to optimise next generation drug development.
  • Data mining to discover potential in both new and old molecules

Professor of Pharmaceutical Technologies
University of Greenwich, UK

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

CEO and Co-Founder
Phenomic AI

Head of Strategy
Horizon Discovery, UK

17.10
Closing remarks
17.20
End of day 2

Analytics & AI for R&D Optimisation

Day 3 - Stream A - 29th January, 2020

Stream Overview

This stream will focus on practical ways to make use of advanced analytics and AI to drive R&D portfolio decision making as well as optimise the efficiency of the early stages of the R&D process. New technologies and software that are advancing the field of data analytics will be examined, particularly regarding AI powered solutions that are accelerating drug discovery and enabling better drug performance prediction. Attendees will understand not only the opportunities AI and data analytics present for their R&D strategy, but also how to effectively and efficiently implement them.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

AI AND MACHINE LEARNING FOR R&D

09.10
Data scientists on a chemistry space odyssey

Senior Director Computational Biology, Discovery Sciences
Janssen Research & Development

09.50
Towards an AI-powered validated multi-omics platform to support clinical biomarker research
  • To identify patient selection strategies for complex anti-cancer therapies it is key to thoroughly characterise tumors using a multi-omics approach.
  • A computational platform to enable efficient clinical biomarker research has to address analysis needs of different user groups like bioinformaticians & biostatisticians, translational scientists, clinical researchers.
  • Data from clinical studies need to be integrated with enormous amounts of public data
  • AI and machine learning capabilities are key to address challenges in genomic data processing and digital pathology
  • Through different analytical tool sets, each tailored to needs of user groups, biomarker research teams can jointly work on selected unique sources of biomarker data
Eike Staub

Director, Head of Oncology Bioinformatics
Merck

10.30
Networking & Coffee Break
11.00
Predictive analytics and machine learning in supporting ADME/PK optimization
  • ML models are developed to guide chemistry towards selective use of in vitro assays
  • Advanced project specific data analysis and visualization tools support teams in decision making
  • PBPK based exposure prediction can be an option to support compound selection

Senior Investigator II, Modeling & Simulation, Data Science
Novartis

ADVANCED ANALYTICS FOR DRIVING R&D INNOVATION

11.40
Multivariate data analysis and modeling
Gerald Striedner (TBC)

Ass. Professor
University of Natural Resources and Life Sciences

12.20
Luncheon Break
13.20
Data analytics to improve R&D efficiency
David Ruau

Head of Data Science Advanced Analytics Dept.
Bayer

14.00
DATA - INSIGHTS & FUTURE IMPACT: How R&D Operations analytics can support strategic decision making
  • Integrated project and demand planning with state of the art methodology and tools
  • Dedicated project, portfolio and functional reporting to enable efficient decision making
  • Using data analytics to optimise R&D processes

Senior Strategic R&D Operations Analyst
Merck

14.40
Networking & Coffee Break
15.10
Panel Discussion: Opportunities for advanced analytics and AI to improve R&D
  • Developing an AI-powered technology solution for accelerated drug discovery and better drug performance prediction ability
  • Turning analytics into actionable insights that further innovation
  • Effectively using predictive analytics, intelligent algorithm design and machine learning in R&D process
  • Using analytics and AI to drive portfolio decision making

Senior Director Computational Biology, Discovery Sciences
Janssen Research & Development

Eike Staub

Director, Head of Oncology Bioinformatics
Merck

David Ruau

Head of Data Science Advanced Analytics Dept.
Bayer

Senior Investigator II, Modeling & Simulation, Data Science
Novartis

16.00
Closing remarks
16.10
End of day 3

Training Workshop: Persuasion & Negotiation Skills for Scientific & Technical Professionals

Day 3 - Stream B - 29th January, 2020

Essential tactics to engage and understand stakeholders, influence them and communicate the value of your solutions or opportunities.

This unique training course is specifically tailored towards life science professionals who need to learn powerful soft skills. Those who attend will engage more external stakeholders (KOLs, Clinicians, MoH) or customers, stand out from the competition, overcome objections and better "sell" the true value of their solutions, proposals or opportunities

What's the unmet need?

We at NextLevel Life Sciences, have a unique perspective on how life science professionals can dramatically and immediately improve their influence & persuasiveness. At our industry events, we constantly observe our clients’ successful interactions, but also missed opportunities. For example, many executives in life sciences companies are true subject-matter or technical experts. Often, however, they haven't received any structured training on negotiation, influence and persuasion, so are not maximising their chances of ensuring the most from each customer interaction.

We have recognised a strong need for a structured and interactive course which will definitely help life sciences professionals to engage stakeholders, appreciate their needs, positively influence them, demonstrate true value and forge lasting business relationships.

Who are your trainers?

Geoff Cable                               
CEO & co-Founder                         
NextLevel Life Sciences
 

Luke Rogers
CEO & co-Founder
NextLevel Life Sciences


"We believe that sales isn't a job, it's a life skill"

Geoff and Luke are experts in soft skills, negotiation, business development, management & entrepreneurship. They have a strong track record of growing their successful company organically, through sales and marketing. Both are Australians and also CEOs and co-founders of NextLevel Life Sciences, a leading event organiser and business intelligence provider for the Biopharma and Medtech industries. Over the last 12 years, Luke and Geoff have developed, promoted and delivered hundreds of industry events, focused on cutting-edge or critical themes. These have involved thousands of senior-level attendees from all the major pharma, medtech, biotech and diagnostics companies, as well as a broad range of service providers and key industry stakeholders. NextLevel Life Sciences has a strong value proposition, an effective process, but especially a customer-centric sales philosophy.

08.30
Welcome & Icebreaker
09.00
Understanding your stakeholders and what they see as "Value"
  • Who are your different customer types?
  • Defining your unique value proposition: Features Vs Benefits
  • Making your proposal/offer stand out amidst the noise
  • Activity: Personal & Product features & Benefits
10.00
Break
10.15
Building magnetic rapport: Making the most out of your customer interactions
  • How to quickly engage people and avoid awkwardness
  • Striking up conversations
  • Verbal & non-verbal communication for maximum impact
  • Role Play: Initial Engagement:
    • ​Conference Booth / Poster Presentation
    • New Colleague
    • KOL / Clinical Site
11.00
Identifying Needs through powerful Questioning & Listening
  • Why are most people bad listeners?
  • Directed questions to help you achieve your outcomes
  • Quickly defining your customer’s needs
  • Activity: Active listening in action
  • Role Play: Which benefits to leverage in which situation?
12.15
Lunch Break
13.00
The Mindset & Strategy of Successful Negotiators
  • What mentality will allow you to reach your win-win outcome?
  • How not to lose out: Maintaining control over the range of outcomes
  • Self-Awareness & Personal Preparation: Badly needing an agreement Vs Being able to walk away without one.
  • Leveraging the power of your solution as opposed to a product/service
  • Priming the negotiation & using "Halo-effect" to improve outcomes for all
  • Defining your key success criteria & limits before the process

Activity: What are the common strategies used in negotiations & when to use them?

14.00
Break
14.20
How to be more persuasive & What to do when you hear "No"
  • Best practice steps to handling objections
  • Gently challenging your customer to think differently via smart questions
  • Storytelling as an emotional persuasion tool
  • Minimising the perceived risk vs your strong value proposition
  • Understanding why the partner is saying "No"
  • Activity: Developing a customized objection handling roadmap for your product/service
  • Activity: Developing storytelling for your common & expected objections
16.00
Fast Follow Ups / Stimulating Action after Negotiations & Proposals
  • Ensuring your proposal/offer is not de-prioritized by customers
  • Stimulating action on your terms, quickly!
  • Activity: Developing personal urgency message to stimulate faster action from a stakeholder
16.30
Personal Development Plan & Key Take-Aways
17.00
End Of Workshop

Senior R&D executives: Scientific Officers, Chief Information Officers, Chief Technology Officers, Knowledge & Data Management (Discovery, Clinical & Real-World Data), R&D Analytics, Informatics, R&D Innovation, External Alliances & Innovation, R&D Strategy.

Drug Discovery: Drug Discovery, R&D, Lead Identification & Target Validation, Screening, Translational R&D, Genomics & Proteomics, Biomarker R&D, Senior Scientist, Biostatistics, Biometric, Precision Medicine, Personalised Medicine, Computational Biology

External Innovation: Business Development, Strategic Collaborations, Alliances, External Innovation, Consortia, Partnerships

R&D Analytics & AI: Data Analyst, Data Scientist, Bioinformatician, Bioinformatics, CIO, AI, Machine Learning

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Speaker Biographies

Alexander Scheer

Chief Scientific Officer
ERYTECH Pharma, France

Alexander Scheer has more than 20 years of experience in R&D and the life science industry both in Pharma and Biotech. Prior to joining ERYTECH as Chief Scientific Officer in 2016, he was the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research. Before, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where he led Merck’s program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). At Serono, he served as Head of Molecular Screening and Cellular Pharmacology Department. Before joining industry, he was assistant professor at the University of Lausanne, Switzerland. Dr. Scheer holds M.Sc. in Chemistry from the University of Gottingen and a Ph.D from the German Cancer Research Center in Heidelberg

Alexander Krupp

Head of Computational Life Science IT
Bayer

Dr. Alexander Krupp heads the department “Computational Life Science IT” for Research, Development, Drug Safety and Medical Affairs of Bayer Pharmaceuticals. His department focuses on integrating information across the value chain and on improving scientific and managerial insight generation by advanced analytics.

Dr. Krupp is passionate about bringing digital innovation to the pharmaceutical industry to enable the invention of novel medicines that will benefit millions of patients. His recent activities have comprised the creation of an architecture competency cluster, digital strategy definition as well as the introduction of processes and governance bodies to achieve this company goal.

Prior to his current position, he has consulted clients in the LifeScience industry in strategy, business process redesign, digital transformation, value stream analyses, carve out and portfolio optimization. Dr. Krupp holds a M.Sc. in Biochemistry and a PhD in Neuroscience. Beyond his technology background, his scientific expertise is focused on oncogenic signaling and growth factor receptor signaling as well as neurophysiology and the molecular basis for learning and memory.

Michael Frank

Director,Strategy- World Wide Research and Development
Pfizer, USA

Michael is a Director of Strategy in Pfizer’s World Wide R&D organization.  His group supports  strategy and innovation in pharmaceutical development across all therapeutic areas.  His current focus is expanding the role of Artificial Intelligence in drug discovery to increase productivity and identify new therapies to help patients. 

Prior to Pfizer, Michael was a Strategy Consultant at Strategy& (a PWC company) and PA Consulting.  He was also VP of technology at Phosplatin Therapeutics, a NYC biotech startup. 

Michael lives in Brooklyn, and in his spare time enjoys helping entrepreneurs get their ideas to market; with several successful launches, from KickStarter to biotech IPOs. His own inventions include a kitchen gadget for SkyMall, a dual language eReader App, and several medical diagnostics and products.

He has an MBA from Columbia Business School, and MS in Biomedical Engineering from Boston University, and a BA in Biology from University of Michigan.

Pieter Peeters

Senior Director Computational Biology, Discovery Sciences
Janssen Research & Development

Pieter Peeters is heading the European computational biology team in Discovery Sciences at Janssen Research & Development. His group is aiding the drug discovery and development teams in Janssen R&D in their search for novel safe and effective drugs by applying both computational as well as wet lab ‘omics approaches. The team is involved data and high content imaging based approaches aiming at comprehensive understanding of drug action.    

Pieter obtained his Ph.D. in Applied Biological Sciences (medical molecular biology) at the Center for Human Genetics from the Catholic University Leuven, Belgium and graduated as a bioengineering (gene and cell technology and interface chemistry) at the same university. During his PhD he studied the role of the ETS-variant gene 6 (ETV6) in different mechanisms for leukemogenesis. This research into the molecular causes of leukemia demonstrated for the first time a role for the JAK2 kinase in the etiology of myeloproliferative neoplasms and leukemias.

Pieter has been the Janssen lead for the ExaScience life lab, a collaborative effort between Intel, IMEC the 5 Flemish Universities and Janssen with the aim of expediting R&D in healthcare by applying high performance computing approaches. In addition, he was the Janssen lead for the Innovative Medicine Initiative project on the application of inducible pluripotent stem cells in drug discovery and drug safety testing (StemBANCC). Currently, his team is utilizing single cell analytical capabilities to enable the exploitation of the immune system for disease monitoring, interception and immunomodulation as well as advanced analytics and machine learning methods to for both evaluating and designing small molecules  expediting drug discovery.

Johan Liwing

Senior Director, Real World Evidence – External Partnerships Global Commercial Strategy Organisation
Janssen

In his current role Johan is coordinating efforts of developing close collaborations between Janssen and other parties around the globe in RWE research and is part of the Global Janssen RWE Leadership team. Furthermore, Johan has developed and led the Janssen team in the collaboration with Karolinska Institutet in advanced real world data analysis since 2015. Before joining Janssen in 2007 Johan worked as a health economist at Roche. Johan has been working with big data analytics in different areas such as finance and engineering before joining the health care sector and has a MSc in engineering physics form the Royal Institute of Technology in Stockholm and a BSc in Business administration from Stockholm University. Over the last decade Johan has developed a research passion for how analysis of routine clinical data, especially in the field of hematology, can be used in decision making.

Benoit Marchal

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

Benoît has an IT Master Degree from the University of Technology of Compiegne (France) and has more than 25 years’ experience leading various digitalization projects to improve and streamline the clinical research process. Before joining Roche, Benoît created and managed the startup NovaXon that provided solutions to pharmaceutical companies and hospitals to collect clinical data. Previously he worked for Medtronic in a special innovation department to explore new therapies with active medical devices. Most recently, he took the position of Roche representative in the industry collaboration EHR4CR and became a strong advocate both internally and externally of the potential of hospital real world data to support medical research. In parallel Benoît, is leading several innovation proposals to address some of the common challenges observed in precision medicine.

Paul-Michael Agapow

Health Informatics Director,
AstraZeneca, UK

Originally a biochemist & immunologist, Paul was an early convert to the promise of informatic & computational biology, bringing it to evolution, infectious disease & epidemiology across positions in Australia, South Africa & the UK. More recently, he has been at Imperial College's Data Science Institute, working on biomedical Big Data applications in the clinic and for precision medicine using machine learning & advanced computation, before joining AstraZeneca as Director in Health Informatics.  He is also an organiser of Bioinformatics.London, an occasional talk series held in the capital.

Theo Meert

Head of R&D G3O
Janssen, Belgium

Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Brussels, Hasselt and Ghent.

During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams in the field of CNS (Psychiatry - Addiction - Pain -Neurology/ Alzheimer). The activities of these groups covered the complete drug discovery process from early drug candidate selection to POC and further clinical testing. He was a key driver for several advanced projects in the CNS area leading to marketed drugs. Dr. Meert also supports some Full Development products and is involved in the scientific support of novel and marketed products. Dr. Meert has constructed an extensive network within J&J and external scientific and clinical organizations. He has also built an external network of external partnership initiatives and was instrumental in various novel external innovation models.

Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology in Experimental Psychology at the University of Brussels (1986) and a Ph.D. in Medicine/Anesthesiology at the University of Antwerp (1994).

Peter J. Atkinson

Director, Head of UK Open Innovation Neurology Business Group
Eisai Limited, UK

Peter Atkinson trained as a pharmacologist obtaining a PhD in Cell Physiology and Pharmacology at the University of Leicester.  His neuroscience drug discovery career started in 1998 at SmithKline Beecham (later GSK) and subsequently Wyeth Research (later Pfizer) in the USA.  Joining Eisai in 2010 he led pre-clinical neurology projects at various stages from inception to candidate selection.  In 2014 he transitioned to Eisai’s Neurology Open Innovation function which he now leads.   In this role he manages strategic external alliances with academia and biotech partners with a goal of identifying novel treatments for neurodegenerative diseases.

Katrin Zitto

Senior Strategic R&D Operations Analyst
Merck

Katrin Zitto is a Senior Strategic R&D Operations Analyst at Merck Healthcare KGaA, where she works on integrated Resource Management for Biopharma R&D.
Before this role she held multiple other roles within Merck e.g. in Global Clinical Operations and as Corporate Sourcing Manager in the Procurement department.
Katrin holds a Master of Science degree in Biotechnology from the University of Applied Science in Mannheim.

Evelien Micholt

AI Innovation Lead
UCB

Holding a PhD in Bio-Engineering, skilled in interaction design and currently being in the position of AI innovation lead at UCB, Evelien is a typical example of the 'never-not-learning' generation in these fast evolving times. In the transversal AI team at UCB, Evelien is responsible for bridging the "idea to roll-out" process of software solutions fueled by data & AI, in an Agile manner.

Joerg Berghausen

Senior Investigator II, Modeling & Simulation, Data Science
Novartis

Joerg is leading the Data Science Team in the Pharmacokinetics Sciences section within Translation Medicine. He is a physico-chemist by training and has gained broad experience in supporting project teams during lead optimization. During his career in pharmaceutical industry, he worked on solid-state characterization, formulation support for PK and toxicological studies, determination of physico-chemical parameters and various ADME properties. He represented ADME and PK sciences in various project teams in discovery phase and got involved in data science and modeling due to his interest in ADME property models and PBPK predictions.

Maria Maccecchini

President & CEO
QR Pharma

Maria Maccecchini founded Annovis Bio, Inc. to develop treatments for Alzheimer’s (AD), Parkinson’s (PD) and other neurodegenerative diseases by normalizing axonal transport and restoring homeostasis in the brain.

The company is developing three classes of drugs for the treatment of neurodegeneration. One targets chronic conditions like AD and PD and may stop the progression of the diseases. The second one targets acute conditions, like Traumatic Brain Injury and Stroke. Whereas the third one targets late stage AD and may stabilize the decline. ANVS-401, the lead compound, successfully completed 3 phase I studies demonstrating that it is safe and well tolerated;  enters the brain; restores axonal transport by normalizing brain levels of neurotoxic proteins back to the levels seen in healthy normal volunteers; reduces inflammation and protects nerve cells from dying. ANVS-401 totally recovered memory and learning in AD mice, restored normal gut motility and movement patterns in PD mice. While ANVS-405 prevented cognitive decline in TBI rats and blindness in acute glaucoma rats. ANVS-401 is presently is being tested intwo phase 2a clinical studies, one in early AD and on in early PD patients

In between her first and second company Dr. Maccecchini joined two angel group funds – Robin Hood Ventures and Mid-Atlantic Angel Group. She mainly invests in the life science sector. She serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade, women, charitable and not for profit organizations.

In 1991 she started her first biotech company—Symphony Pharmaceuticals – to protect nerve cells from dying in stroke. After acquiring a Scottish and a Japanese company, Symphony later changed its name to Annovis. The company was acquired by Transgenomic Inc. in 2001.

Before that she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a 2-year visiting fellowship at The Rockefeller University.

Liam Good

CSO
Tecrea, UK

Liam is a founding Director at Tecrea Ltd. Liam’s first post graduate employment was within wineries and breweries, where he developed a passion for microbiology. He next completed a PhD in Canada on yeast genetics and then postdoctoral training at the Department of Cell and Molecular Medicine at the Panum Institute in Copenhagen. Liam was next a group leader at the Department of Cellular and Molecular Biology at the Karolinska Institute in Stockholm. Liam is now a Professor of Microbiology and Biotechnology and Dean for Innovation at the Royal Veterinary College, University of London. Liam sits on several scientific advisory and strategy boards.  His research and innovation interests include nanomedicine, antimicrobials, antimicrobial resistance and cellular delivery technologies.

Jan Hoflack

CSO/COO
Oncodesign, France

Dr. Hoflack is the CSO/COO of Oncodesign S.A., a France based biotechnology company, with over 32 years’ experience in the field of Drug Discovery and Development in international companies. Jan moved into the small life science company world after 22 years as a senior executive in major pharma companies (Sanofi, Novartis, AstraZeneca, Johnson & Johnson). He is a strong believer in the open innovation model, based on productive partnerships that combine the strengths of "big pharma" and small innovation companies. As creator of the Nanocyclix medicinal chemistry platform for next generation macrocyclic kinase inhibitors, Dr Hoflack initiated multiple international collaborations around Oncodesign’s probe based drug discovery process. Following Oncodesign’s IPO in 2014, the company is  advancing a number of internal programs on unexplored and intractable kinases with high potential in oncology, neurology and inflammatory diseases. In 2016 these programs were strongly accelerated following the acquisition of a former GSK R&D site in Paris, France. Oncodesign is now established as a leader in next generation kinase inhibitors, and as an emerging and sustainable biopharmaceutical company.

Sinanudin Omerhodzic

Senior Vice President Information Technology
Hartmann Group, Germany

Born in Berlin. Graduate IT on Technical University of Berlin.
Experienced Technology Leader in setup of corporate digital technology innovation teams with the entrepreneur mindset (“act as a growth accelerator by proactively utilize modern technologies to implement new business models) for different industries such as healthcare, automotive, airspace and industry.

Hobbies: Soccer trainer and compose music on piano

Career Path:

CIO & Senior Vice President, Paul HARTMANN AG (actual role since January 2017)
Business Technology Leader EMEA, Johnson & Johnson (2015 - 2017)
Global IT Director, Trelleborg (2011 - 2015)
Head of IT, Sonova Holding (2008 – 2011)
Head of IT Europe, Sonic Innovation (2003 – 2008)

Nazar Rasul

Global Head of Technology & Innovation Management
Siemens Healthcare

Nazar has been within Siemens since more than 15 years, with strong professional background in R&D, technology and digitalization strategy, realization of digital agenda, strategic innovations on corporate level, industrial and healthcare IT, innovation program management.

His current position is Global Head of Technology & Innovation Management within company CTO organization. He used to work several years until 2015 for Siemens Corporate Technology within Strategic Marketing&Visioning as Project Director with focus on strategic innovation management and future visions.

Between 2003 and 2009 he was Head of SW development within Medical Electronics and Imaging Solutions at Siemens Healthcare in Germany. He started his carrier earlier at Siemens Medical Solutions in Sweden as Technical Project Manager for Angiography systems for cardiology and neurology applications.

He holds a Ph.D. degree in Engineering / Automated systems and an MBA in General Management.

Andreas Weinhäusel

Thematic Coordinator Molecular Diagnostics Center for Health & Bioresources
Austrian Institute of Technology, Austria

AW by his profession is biotechnologist and associate professor for molecular biology at the University of Natural Resources and Applied Life Sciences, Vienna. 

Working from 1995-2004 at the Children’s Cancer Research Institute, Vienna, he is experienced in human molecular genetic diagnostics and specialized on diagnostic-testing of syndromal and hereditary neoplastic disease. In 2001 AW obtained the post-doctoral graduation “Specialist in Human Genetics”.  Since 2004 at the Molecular Diagnostics business-unit of the AIT-Austrian Institute of Technology he specialized on DNA-methylation- and autoantibody -biomarker development using microarray and high throughput technologies.

Jeremy Everett

Professor of Pharmaceutical Technologies
University of Greenwich, UK

Jeremy Everett is the Professor of Pharmaceutical Technologies at the University of Greenwich UK. In addition, he is a Visiting Professor in the Department of Surgery and Cancer at Imperial College and at the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore, where he is also a Scientific Consultant.

He previously held a variety of global drug discovery technology leadership positions for Pfizer and SmithKline Beecham, including responsibility for drug target analysis, drug design, drug lead generation, analytical sciences, biobanking, screening file management, high throughput screening (HTS), and structural biology. He is a consultant on drug discovery and on pharmaceutical patent litigation.

Jeremy conducts research in metabonomics and pharmaco-metabonomics, in which he has worked for over 30 years, including co-naming and defining both areas. He is a co-discoverer of pharmacometabonomics. Current work is focused on genotype – metabotype correlations in the areas of obesity and ageing.

Jeremy received both his BSc and PhD in chemistry from Nottingham University, UK. He did post-doctoral studies at McMaster University and at McGill University in Canada.

Jeremy is a Fellow of the Royal Society of Chemistry and a Chartered Chemist, a Member of the American Chemical Society, a Fellow of the Higher Education Academy and is an author or co-author on 99 peer-reviewed publications and several patents, with over 4,400 citations to date and an h-index of 29. He has delivered over 60 invited lectures.

Winston Hide

Co-Director Noncoding RNA Core
Institute for RNA medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, USA

Hide performed post-doctoral training in molecular evolution at the University of Texas in Houston with Wen Hsuing Li, also at Baylor College of Medicine at Human Genome Centre with Richard Gibbs and also at the Smithsonian Museum of Natural History in Washington DC. His first paper, published in Nature, was a controversial analysis of rodent evolution - using molecular phylogenetics he questioned the membership of guinea-pigs in the rodentia.

 

His career began as a director of genomics at MasPar high performance computer corporation in Silicon Valley, California. Returning to South Africa to found and direct the South African National Bioinformatics Institute (SANBI) at the University of Western Cape in 1996, he established the first PhD programme in Bioinformatics in Africa and is a founder of the African Society of Bioinformatics and Computational Biology and was the first African on the board of the International Society of Computational Biology. At SANBI he founded the Medical Research Council Unit for Bioinformatics Capacity Development and established the WHO regional Training Center for bioinformatics. An author of the National Biotechnology Strategy for South Africa he founded the South African National Bioinformatics Network. Focusing on the development of Africa’s peoples he is a founder member of the steering committee that established the NIH-Wellcome Trust funded Pan African H3 Africa Genome Initiative. Together with a group from the World Health Organisation, Yale University, and the UK Sanger Center he established the International Glossina Genome Initiative in 2005 which culminated in the publication of the Tsetse Fly genome in 2014.

Hide has been recognised for these activities by receipt of the first International Society for Computational Biology award for outstanding achievement.

As Associate Professor of Bioinformatics and Computational Biology in the Department of Biostatistics at Harvard School of Public Health he has led development of personal genomics approaches to public health and directed the Center for Health Bioinformatics. Hide developed the bioinformatics strategy for the Harvard Stem Cell Institute and was Director of its Center for Stem Cell Bioinformatics where he built a science commons for data sharing and integration.

After 4 years as Chair in Computational Biology at the University of Sheffield Institute for Translational Neurosciences where he drove of systems approaches to genome medicine as Director of the Centre for Genome Translation, Hide has recently returned to Harvard.

His research at Beth Israel Deaconess Medical Center now addresses systems biology of RNA medicine to deliver clinical translation of genomics for application to repurposing of drugs, to determine prioritised drug targets and to deliver prediction to predisposition to disease. He uses standardized approaches to discovery in complex neurodegenerative diseases such as Alzheimer’s. Hide directs the bioinformatics for the Alzhiemer’s Genome Project  (Cure Alzhiemer’s Foundation) where he has built the computational infrastructure for, and analyzed 1400 whole genome sequences from patients with the disease and is a driving member of the CureAD CIRCUITS consortium, a group made up of scientists from Harvard, MIT and UCSF funded by the Cure Alzhiemer’s Foundation to determine the regulatory processes that go awry in Alzheimer’s.

Honours: Hide has received the South African National Research Foundation Presidents’ award, the Oppenheimer Trust Sabbatical Award and the first International Society for Computational Biology; Outstanding Achievement award.

Academies: Elected member of the Academy of Science of South Africa.

Michel Goldman

Founder
Institute for Interdisciplinary Innovation in healthcare, Université Libre de Bruxelles, Belgium

Michel Goldman (born 1 January 1955) is a Belgian medical doctor specialized in immunology and internal medicine. He is the Founder and  co-Director of the Institute for Interdisciplinary Innovation in healthcare and a Professor of immunology at the Université libre de Bruxelles (ULB).

He was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI), from 2009 to 2014. With a €2 billion budget provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he was responsible for 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer's dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety. During his mandate, he established privileged contacts with major European academic centers as well as large pharmaceutical companies and biotech companies active in healthcare worldwide.


From 1990 to 2008, he was the Director of the Department of Immunology-Hematology-Transfusion at the Erasme Hospital in Brussels and from 2009 to 2014 he serves as the first Director of the Institute for Medical Immunology at ULB.

 

Besides his academic duties, Michel Goldman is the Editor-in-Chief of Frontiers in Medicine, a Senior Fellow of Fastercures, a branch of the Milken Institute, a member of the Board of the European Tuberculosis Vaccine Initiative, of the Scientific Board of the Quebec - Clinical Research Organization in Cancer (Q-CROC), and of the Governing Board of the French National Institute of Health and Medical Research (INSERM).

Michel Goldman’s scientific achievements resulted in more than 400 articles in peer-reviewed journals and the Thomson Institute recognized him as ISI Highly Cited Scientist for Scientific Information. In 1992, he shared the Lucien Steinberg Prize with Pr. Peter Piot. In 2000, he was the laureate of the Quinquennial Prize of the Belgian National Fund of Scientific Research for Clinical Sciences. He held in 2001 the Spinoza chair at the University of Amsterdam. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université of Lille.

Sam Cooper

CEO and Co-Founder
Phenomic AI

Sam recently finished his PhD at Imperial College London and the Institute of cancer research, under the supervision of Prof. Robert Glen an early pioneer of chemoinformatics, and Dr. Chris Bakal a leader in high-content screening. Over this period Sam used novel machine learning methods to answer questions in biology and drug discovery, publishing 12 times over a 4-year period, and winning industry led competitions. During this time, he also organized conferences in the field and met Oren Kraus, his co-founder at Phenomic AI and one of the first researchers to use deep-learning on biological data. Together they set-up Phenomic AI an early stage biotech, based in Toronto, backed by $2.25m in Silicon Valley and Canadian VC funding, and with >$1m in industry contracts. Phenomic is now racing to commercialize a platform for high-content screening of therapeutic Ab, that integrates wet-lab automation with state-of-the-art analysis techniques. 

Brian Burke

Head of Strategy
Horizon Discovery, UK

Brian joined Horizon in August 2012 as a Business Development Manager and was promoted to Global Head of Strategy during 2018. In this role, he is responsible for driving strategic development and execution across the Horizon business. He works closely with other functions to analyse and impact the wider Horizon opportunity in order to build value more effectively.

Before joining Horizon, Brian worked successfully in a number of commercial and licensing roles with a particular focus on gene editing, bioproduction and next generation sequencing. Prior to moving to industry, he gained a first class honours degree from the University of Glasgow and a PhD from Leeds University.

Grazia Frontoso

Data Analytics Specialist
Google Cloud, Switzerland

Grazia Frontoso is a Data Analytics Specialist at Google Cloud in charge of supporting enterprise customers in Switzerland in digital transformation and Big Data analytics for the healthcare & life science sector. Before joining Google, she worked for several years as Software Product manager in risk management designing cloud solutions for regulated industries. She holds a PhD in physics and is passionate about the transformational power of technology.

Previous Attendees at R&D Data Intelligence Leaders Forum - Basel, Switzerland, 2019

Company
Job Title
2KMM
CEO
2KMM
Data Management and Analysis Assistant
Almirall S.A
Molecular Informatics R&D Specialist
Almirall S.A
R&D IT Business Partner & SVC Delivery
Amgen Switzerland
Medical Director
aparito
Founder & CEO
Bayer
IT Business Partner
Bayer
IT Business Partner Research
Bayer
Director, Medicinal Chemistry
Bayer Business Services GmbH
IT Business Partner Medical Affairs & Pharmacovigilance
Bayer Consumer Care
Digital GxP Compliance Manager
Biogen
Principal Scientist
Boehringer Ingelheim
IT Architect
Catholic University of Korea
Professor
Center for Research and Interdisciplinarity (CRI)
Managing Director
ChemAxon
Account Manager
ChemAxon
Senior Application Scientist
CSL Behring
Head Breakthrough Technologies
CureVac
Co-founder and Chairman of the Supervisory Board
Dacadoo
President and CEO
Databricks
Life Sciences Lead
Deloitte ConvergeHEALTH
Senior Manager
Deloitte UK Centre for Health Solutions
Research Manager
DNAnexus
CEO
docdok.health
Co-Founder & CEO
e-therapeutics
Head of Discovery Informatics
European Connected Health Alliance
Chair
Evonetix
CEO
Exscientia
Head of Chemoinformatics
F. Hoffmann-La Roche
Biology Workflow Team Leader
F. Hoffmann-La Roche
Head of Small Molecule Discovery Workflows
F. Hoffmann-La Roche
Research Informatics Scientist
F. Hoffmann-La Roche
Principal Scientist
F. Hoffmann-La Roche
Senior Scientist
F. Hoffmann-La Roche
Personalised Healthcare CoE
F. Hoffmann-La Roche AG
Head of Business Intelligence Finance, Operations, Site Services, Q&R Analytics
F. Hoffmann-La Roche Ltd
Group Manager EU/International Clinical Trial Regulatory Management
FeetMe
Co-founder and CEO
GE Healthcare
Global Digital Services Transformation Leader
Genedata
Business Development Manager
Getinge
Systems Architect
Google Cloud
Sr. Program Manager, Healthcare & Life Sciences
GSK
Head Computational Biology and Stats
Helbling
Head of Development
Helbling
Development Engineer
Hoffmann La Roche
Strategic Analytics Manager
icometrix
CEO
Idorsia Pharmaceuticals
Head of Translational Science
Iktos
Founder and CEO
Iktos
CSO
Image Analysis Group
CEO
Insilico Medicine
CTO
Intellegens
CTO
Janssen Pharmaceuticals
Senior Associate Scientist
Johnson & Johnson
Associate Director Integrated Clinical & Operational Analytics
Linguamatics
Senior Account Manager, Europe
Lupus Friends and Family Foundation
Founder & President
Medisafe
VP Pharma (EMEA)
Medtronic
EMEA privacy consultant
Merck Sharp and Dohme
Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Nebion
CEO
Nebula Genomics
Co-founder
NHS Foundation Trust
Director of Innovation and Development
Novartis
Global Head Technology, Architecture, Digital Drug Development
Novartis
Associate Director, Information Systems
Novartis
Global Head of Portfolio Management, Medical, Digital and RWE Solutions
Novartis
Asc. Director Knowledge Management
Novartis
Data Science & A.I. Technical Advisor
Novartis
Head Data Governance
Novo Nordisk A/S
Senior Director
Novo Nordisk A/S
Head of Non-clinical Data Management
Novozymes
R&D Director, BioEnergy
Novozymes
Group Leader, Automation and Digitalization, R&D
Numerate
CSO
Philips
Principal Scientist - Medical Biomarker Research Oncology
Philips Research
Vice President, Member Program Board Healthcare Healthcare Strategic Partnerships
Pierre Fabre
BioInformatics Platform Director
Pool Global Partners
Entrepreneur in Residence
Pool Global Partners, USA
Founder and Managing Partner
Quantitative Biology Center Tübingen
Centre Head
Roche
Senior IT Project Manager Specialized in Health IT
Roche
Group Head Clinical Trials, Regulatory Management
Roche
Principal Scientist, Toxicology Project Leader
Roche Innovation Center Basel, Switzerland
Principal Scientist, Scientifc Information Management
Sanofi
Director of scientific relations R&D Europe
Shivom
Founder & CSO
Siemens Healthineers
Head of Digital Technology & Innovation
Technical University Dresden
Professor in Bioinformatics, BIOTEC and Dept. of Computing
TheraPanacea
Chief Executive Officer / Chief Scientist
Thomas Jefferson University and Jefferson Health System
Chief Digital Officer and Senior Vice President for Technology Innovation and Consumer Experience
University of Colorado
Distinguished Professor
University of Southampton
Research Fellow , Clinical Informatics Research Unit
University of Surrey
Professor of Machine Intelligence
University of Zurich
Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB)
Zebra Medical Vision
Co-Founder and CTO

Related Videos

Presentation

Measuring the return from pharmaceutical innovation 2018

Related topics: Discovery & R&D Innovation, Digital & Technology
Availability: FREE

The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.

Speaker

Mark Steedman
Research Manager
Deloitte UK Centre for Health Solutions

Presentation

Extreme-Scale Cloud-Based Infrastructure needed for global genomic data

Related topics: IT & Big Data
Availability: FREE
  • Cloud genomic data sets are approaching a total of 250 Petabytes representing an unprecedented resource for research and clinical applications
  • Extreme-scale cloud-based compute and tools are required to federate and utilize the emerging global resource, conforming to localized compliance requirements
  • A rapid evolution in data resource architecture and applicable tools is required, with an important role to be played by Artificial Intelligence
Speaker

Richard Daly
CEO
DNAnexus, Inc., USA

Pricing & Registration

3 Day Delegate Pass
Ultra Early-Bird prices until 31.08.2019!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,092 EUR
After 25% discount
2 Delegates
1,395 EUR
After 50% discount
3 Delegates
1,395 EUR
After 50% discount
4+ Delegates
1,395 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,790 EUR
2 Delegates
2,511 EUR
After 10% discount
3 Delegates
2,371 EUR
After 15% discount
4+ Delegates
2,232 EUR
After 20% discount
Academic
1 Delegate
1,150 EUR
2 Delegates
1,150 EUR
3 Delegates
1,150 EUR
4+ Delegates
1,150 EUR
2 Day Delegate Pass
Ultra Early-Bird prices until 31.08.2019!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
1,717 EUR
After 25% discount
2 Delegates
1,145 EUR
After 50% discount
3 Delegates
1,145 EUR
After 50% discount
4+ Delegates
1,145 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,290 EUR
2 Delegates
2,061 EUR
After 10% discount
3 Delegates
1,946 EUR
After 15% discount
4+ Delegates
1,832 EUR
After 20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR

Upgrade your Attendance to become a Member!

(Only available for corporate registrations)

Upgrade to Silver Member (Add €199 to your current registration) and receive:
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300 more added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at €999
Upgrade to Gold Member (Add €999 to your current registration) and receive:
  • Free Event Pass - Attend an additional (one) NextLevel Event (in the 12 month period from your event’s dates). Just inform your NextLevel representative which event!
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300+ videos added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at over €3780

For more information click here to learn more: https://www.nextlevells.com/membership